Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.41 |
| ▸ | EIF4E | P06730 | 1/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 10/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21001489 | 0.91 | MKNK1 (0.44) | BRD4MKNK1MKNK2USP30PIM1 | |
| SCHEMBL21001490 | 0.91 | MKNK1 (0.44) | BRD4MKNK1MKNK2USP30PIM1 | |
| SCHEMBL24066309 | 0.91 | MKNK1 (0.44) | BRD4MKNK1MKNK2USP30PIM1 | |
| SCHEMBL30845790 | 0.90 | MKNK1 (0.47) | BRD4EIF4EMKNK1MKNK2USP30 | |
| SCHEMBL21033937 | 0.85 | KDM4E (0.47) | BRD4EIF4EMKNK1MKNK2USP30 | |
| SCHEMBL21033297 | 0.83 | USP30 (0.43) | BRD4USP30PIM1PIM2PTGS1 | |
| SCHEMBL30828901 | 0.81 | MKNK1 (0.50) | EIF4EMKNK1MKNK2USP30PIM1 | |
| SCHEMBL21033166 | 0.79 | USP30 (0.55) | USP30PIM1PIM2PTGS1PTGS2 | |
| SCHEMBL24066044 | 0.78 | MKNK1 (0.45) | MKNK1MKNK2USP30EGLN1 | |
| SCHEMBL31704583 | 0.76 | KIT (0.46) | BRD4EIF4EMKNK1MKNK2PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210371431-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | JUBILANT EPISCRIBE LLC | 2021-12-02 | — | — | US | disclosed |
| WO-2019102494-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2019-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210371431-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | BRD4 384/4885EIF4E 1073/4885MKNK1 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.